Insights into ASX Stocks
.webp&w=828&q=75)
Emyria (ASX: EMD): Sydney Clinic Opens as Treatment Network Expands
Emyria (ASX: EMD) has opened its first Sydney Empax clinic, expanding its treatment network to four Australian states. The new facility adds treatment capacity, while patient volumes and reimbursement arrangements remain key factors in its commercial development.
Dateline Resources (ASX: DTR): National Security Case Gives Colosseum Rare Earths Bid New Life
Dateline Resources (ASX: DTR) has gained US Department of War backing in its bid to restart Colosseum, a gold and rare earths project in California, as a key court hearing nears.
Data#3 (ASX: DTL): 40% Profit Jump from One-Offs, but Can Growth Last?
Data#3 (ASX: DTL) expects first-half profit before tax to jump more than 40%, helped by one-off deals and extra interest income. Investors now weigh whether full-year earnings growth can hold up.
Hormuz Tensions and Rising Oil Prices: 3 ASX Stocks Set to Benefit from Rising Prices
Hormuz tensions are driving oil volatility, influencing Australia’s inflation and ASX performance. Woodside, Karoon Energy and Ampol offer exposure to higher energy prices or refining margins, but operational challenges, market turbulence and potential de-escalation remain key investment risks.
Critica (ASX: CRI): Recent Breakout Meets New Fundamental Signals From Mt Lindsay
Critica (ASX: CRI) released a Mt Lindsay Scoping Study showing a $1 billion NPV underground tin-tungsten operation, though shares eased on the day. With funding pathways still being explored, the company continues advancing its Jupiter rare earths project in parallel.
Excite Technology Services (ASX: EXT): $3.2M Government Renewal Puts Cyber Turnaround to the Test
Excite Technology Services (ASX: EXT) has locked in a $3.2 million, 24-month extension with a federal agency, its first big win since restructuring, as the cybersecurity small-cap works to prove its turnaround.